$15.00-0.44 (-2.88%)
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell ki...
European equities traded in the US as American depositary receipts were trending higher late Tuesday
European equities traded in the US as American depositary receipts were tracking lower late Friday m
European equities traded in the US as American depositary receipts were tracking higher late Thursda
European equities traded in the US as American depositary receipts were tracking higher late Tuesday
European equities traded in the US as American depositary receipts started the trading week lower la